{Reference Type}: Journal Article
{Title}: Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis.
{Author}: Emmi G;Bettiol A;Gelain E;Bajema IM;Berti A;Burns S;Cid MC;Cohen Tervaert JW;Cottin V;Durante E;Holle JU;Mahr AD;Del Pero MM;Marvisi C;Mills J;Moiseev S;Moosig F;Mukhtyar C;Neumann T;Olivotto I;Salvarani C;Seeliger B;Sinico RA;Taillé C;Terrier B;Venhoff N;Bertsias G;Guillevin L;Jayne DRW;Vaglio A;
{Journal}: Nat Rev Rheumatol
{Volume}: 19
{Issue}: 6
{Year}: 2023 06 9
{Factor}: 32.286
{DOI}: 10.1038/s41584-023-00958-w
{Abstract}: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, characterized by asthma, eosinophilia and granulomatous or vasculitic involvement of several organs. The diagnosis and management of EGPA are often challenging and require an integrated, multidisciplinary approach. Current practice relies on recommendations and guidelines addressing the management of ANCA-associated vasculitis and not specifically developed for EGPA. Here, we present evidence-based, cross-discipline guidelines for the diagnosis and management of EGPA that reflect the substantial advances that have been made in the past few years in understanding the pathogenesis, clinical subphenotypes and differential diagnosis of the disease, as well as the availability of new treatment options. Developed by a panel of European experts on the basis of literature reviews and, where appropriate, expert opinion, the 16 statements and five overarching principles cover the diagnosis and staging, treatment, outcome and follow-up of EGPA. These recommendations are primarily intended to be used by healthcare professionals, pharmaceutical industries and drug regulatory authorities, to guide clinical practice and decision-making in EGPA. These guidelines are not intended to limit access to medications by healthcare agencies, nor to impose a fixed order on medication use.